Thursday, November 1st, 2012
UniQuest congratulates Vaxxas on its latest industry accolade

Vaxxas Pty Ltd, a UniQuest start-up established in 2011 to commercialise the NanopatchTM vaccine delivery system based on research from The University of Queensland (UQ), has won the Janssen 2012 AusBiotech Emerging Company Award.

The accolade was announced along with two other Janssen 2012 Industry Excellence Awards at the Ausbiotech national conference in Melbourne last night.

Congratulating the Vaxxas team on another award to add to its impressive list of achievements, UniQuest Managing Director, David Henderson, said this award highlighted the value Australian university-based innovations are contributing to health care around the world.

“This award is the fourth positive milestone in recent months for Vaxxas, which is growing in both reputation and capacity to deliver one of the most globally important advances in vaccine technology this decade,” Mr Henderson said.

“There are very few Australian biotechnology companies which could match the number of significant achievements Vaxxas has logged in just over 12 months, including investment and licensing deals as well as wining the Australian Innovation Challenge and the Best Venture Capital Investment at the 2012 Vaccine Industry Excellence Awards, held at the World Vaccine Congress in Washington, DC.”

Vaxxas’ Nanopatch technology originated from Professor Mark Kendall's research group at the Australian Institute of Bioengineering and Nanotechnology (AIBN) within UQ. UniQuest led the initial commercialisation of the Nanopatch technology prior to Vaxxas being formed with a $15 million syndicated investment led by One Ventures with Brandon Capital, Healthcare Ventures, and the Medical Research Commercialisation Fund.

Vaxxas recently appointed an international CEO, David Hoey, as the first step towards establishing operations in Massachusetts, North America, to expand access to global pharmaceutical partners and complement the company's research and development operations based in Queensland.

Earlier this month Vaxxas announced a research collaboration with Merck (MSD). The collaboration will evaluate Vaxxas' proprietary needle free delivery technology that induces robust immune system activation by targeting vaccines to the abundant immunological cells immediately below the surface of the skin. The deal included Vaxxas granting Merck a licence for the technology for commercial use for an undisclosed vaccine candidate.

Contact Profile

UniQuest Pty Limited

Established by The University of Queensland in 1984, UniQuest is widely recognised as one of Australia’s largest and most successful university commercialisation groups, benchmarking in the top tier of technology transfer worldwide. From an intellectual property portfolio of 1500+ patents it has created over 70 companies, and since 2000 UniQuest and its start-ups have raised more than A$450 million to take university technologies to market. Annual sales of products using UQ technology and licensed by UniQuest are running at A$3 billion. UniQuest now commercialises innovations developed at The University of Queensland including the Institute for Molecular Bioscience and its commercialisation partner institutions: the University of Wollongong, University of Technology Sydney, James Cook University, University of Tasmania, Mater Medical Research Institute, and Queensland Health. A recent addition to the company is the Queensland Government-supported ilab technology business incubator and accelerator. UniQuest also provides access to an expansive and exclusive network of independent academics to tailor a consulting or project R&D solution to meet the diverse needs of industry and government, facilitating some 500 consulting, expert opinion, testing, and contract research services each year. UniQuest is also a leading Australasian provider of international development assistance recognised for excellence in technical leadership, management and research. Working with agencies such as AusAID, NZAID, the Asian Development Bank and the World Bank, UniQuest has developed and implemented more than 400 projects in 60+ countries throughout the Pacific, South-East Asia, the Indian sub-continent and Africa.
Leanne Wyvill
P: +61 7 3365 4037


UniQuest congratulates Vaxxas on its latest industry accolade



More Formats

View QR Code